Fate Therapeutics' off-the-shelf cell therapy product platform, including FT819, is gaining significant exposure by being selected for an oral presentation at the prominent EULAR 2025 congress. The ...
While current clinical trials for cardiac regeneration using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) employ immunosuppressive ...
Researchers across discovery and translational biomedicine recognize the critical importance of iPSCs in core applications beyond regenerative medicine. Large, global biobanks offer researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results